Table 4.
Coadministered drug classes with antiretrovirals among the patients included in the study
| Class | All patients, n (%) (n=183) | <50 years, n (%) (n=104) | ≥50 years, n (%) (n=79) | P-value |
|---|---|---|---|---|
| Alimentary tract and metabolism | 105 (57.4) | 48 (46.2) | 57 (72.2) | <0.001 |
| Anti-infectives for systemic use | 77 (42.1) | 45 (43.3) | 32 (40.5) | 0.708 |
| Dermatologicals | 49 (26.8) | 20 (19.2) | 29 (36.7) | 0.008 |
| Musculoskeletal system | 47 (25.7) | 28 (26.9) | 19 (24.1) | 0.660 |
| Nervous system | 47 (25.7) | 23 (22.1) | 24 (30.4) | 0.205 |
| Respiratory system | 44 (24.0) | 23 (22.1) | 21 (26.6) | 0.484 |
| Cardiovascular system | 43 (23.5) | 18 (17.3) | 25 (31.6) | 0.023 |
| Systemic hormonal preparations, excluding sex hormones | 22 (12.0) | 13 (12.5) | 9 (11.4) | 0.819 |
| Blood and blood forming organs | 20 (10.9) | 7 (6.7) | 13 (16.5) | 0.037 |
| Genitourinary system and sex hormones | 18 (9.8) | 5 (4.8) | 13 (16.5) | 0.009 |
| Antineoplastic and immunomodulating agents | 10 (5.5) | 7 (6.7) | 3 (3.8) | 0.518 |
| Sensory organs | 7 (3.2) | 3 (2.9) | 4 (5.1) | 0.467 |
| Antiparasitic products, insecticides, and repellents | 2 (1.1) | 1 (1.0) | 1 (1.3) | 0.845 |